Taysha Gene Therapies SG&A Expenses 2020-2024 | TSHA

Taysha Gene Therapies sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Taysha Gene Therapies Annual SG&A Expenses
(Millions of US $)
2023 $30
2022 $37
2021 $41
2020 $11
2019 $
Taysha Gene Therapies Quarterly SG&A Expenses
(Millions of US $)
2024-09-30 $8
2024-06-30 $7
2024-03-31 $7
2023-12-31 $7
2023-09-30 $9
2023-06-30 $6
2023-03-31 $9
2022-12-31 $7
2022-09-30 $9
2022-06-30 $10
2022-03-31 $11
2021-12-31 $12
2021-09-30 $11
2021-06-30 $10
2021-03-31 $8
2020-12-31 $6
2020-09-30 $4
2020-06-30 $1
2020-03-31 $0
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00